

Dear SMA Community,

As we reflect on SMA Awareness Month, we take this opportunity to celebrate all those who are a part of the SMA community and the future we're building together. We are grateful for those living with SMA and loved ones who share their experiences with others and help inspire our work, the researchers who move science forward, and those who work to advocate and fight for change.

We also congratulate Cure SMA on hosting such a vibrant and electric Annual SMA Conference, which brought together a record-breaking number of community members from across the globe.

Additionally, we were pleased to present the latest updates from our SPINRAZA® (nusinersen) clinical development program at the SMA Research & Clinical Care Meeting; see more information below.

– The Biogen Team

People



Biogen, in partnership with The Mighty, launched two videos this summer featuring caregivers who share more about their experiences. Watch Alyssa's story [here](#) and Leeann's story [here](#).

Check our website for new patient videos and the latest SPINRAZA data: www.SPINRAZA.com

Community Updates

Biogen recently partnered with *People* magazine to develop an article highlighting the unique experiences of two SPINRAZA patients in their 20s – Tori and Morgan – who are lifelong friends.

The inspiring and heartwarming story touches on how the pair of friends navigate life with SMA, their respective treatment journeys, and the benefits of cultivating a mutual support system. Check out the full article on People.com [here](#).



Highlights from Cure SMA 2023 Annual SMA Conference

During the **SMA Research & Clinical Care Meeting hosted by Cure SMA**, Biogen was pleased to make available the following updates:

- Interim efficacy results from the RESPOND study of infants and toddlers treated with SPINRAZA after Zolgensma® (onasemnogene abeparvovec)
- New real-world evidence in infantile onset SMA



Biogen was honored to sponsor the first-ever **Self-Expression Art Exhibit** at the conference!

Featuring original artwork from 22 talented individuals who are impacted by SMA, the exhibit highlighted how community members express themselves through paintings, drawings, poetry, graphic design and digital art, embroidery and other mediums.

Additional Highlights

Muscle & Nerve published five-year data from the NURTURE study of children who initiated SPINRAZA treatment before the onset of clinical SMA symptoms. The publication details the impact of continued treatment with SPINRAZA over the long-term and includes an analysis that assessed how early markers of disease activity can inform expected outcomes in SMA patients treated early in infancy.

INDICATION

SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients.

IMPORTANT SAFETY INFORMATION

Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to monitor for signs of these risks. Seek medical attention if unexpected bleeding occurs.

Increased risk of kidney damage, including potentially fatal acute inflammation of the kidney, has been observed after administration of similar medicines. Your healthcare provider should perform urine testing before you start treatment with SPINRAZA and before each dose to monitor for signs of this risk.

The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome.

These are not all of the possible side effects of SPINRAZA. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking SPINRAZA, tell your healthcare provider if you are pregnant or plan to become pregnant.

Click here to access full [Prescribing Information](#).

This information is not intended to replace discussions with your healthcare provider.